Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Executive Summary
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
You may also be interested in...
Pierre Fabre Launches Pivotal Trial Of Pioneering Prenatal Therapy
The first boy suffering from X-linked hypohidrotic ectodermal dysplasia has been injected with a protein replacement therapy developed by the French firm and the Esperare Foundation while inside his mother's womb.
Too Crowded? ImmuneOncia Looks To Niches To Challenge PD-L1 Space
ImmuneOncia CEO talks to Scrip about the development strategy for its anti-PD-L1 and anti-CD47 pipeline assets as well as the advantages of having Yuhan and Sorrento as its largest shareholders.
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.